Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gellerfors
Mikael Par Gellerfors, Stockholm SE
| Patent application number | Description | Published |
|---|---|---|
| 20100311008 | ORAL TONGUE POSITIONING DEVICE - The invention relates to a device for positioning the tongue for the treatment of disorders including snoring and obstructive sleep apnoea (OSA) and OSA Syndrome, comprising an anchoring body ( | 12-09-2010 |
Par Gellerfors, Lidingo SE
| Patent application number | Description | Published |
|---|---|---|
| 20090155246 | Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof - The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils. | 06-18-2009 |
| 20090258009 | PROTOFIBRIL SELECTIVE ANTIBODIES AND THE USE THEREOF - The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(CIq) binding, effective in clearance of Aβ protofibrils and with reduce risk of inflammation. | 10-15-2009 |
| 20120076726 | PROTOFIBRIL SELECTIVE ANTIBODIES AND THE USE THEREOF - The invention relates to an isolated antibody, or fragment thereof, having high affinity for human Aβ protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof. | 03-29-2012 |
Pär Gellerfors, Lindingo SE
| Patent application number | Description | Published |
|---|---|---|
| 20110052498 | Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders - A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody. | 03-03-2011 |
Pär Gellerfors, Lindingo SE
| Patent application number | Description | Published |
|---|---|---|
| 20110052498 | Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders - A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody. | 03-03-2011 |
Pär Gellerfors, Lidingö SE
| Patent application number | Description | Published |
|---|---|---|
| 20090155246 | Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof - The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils. | 06-18-2009 |
Pär Gellerfors, Stockholm SE
| Patent application number | Description | Published |
|---|---|---|
| 20120100129 | N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders - A vaccine for delaying onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual comprises a therapeutically effective amount of a physiologically acceptable protofibril/oligomer comprising N-terminal truncated Aβ. An antibody for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual binds one or more truncated AO protofibrils/oligomers, but exhibits no or substantially no cross-reactivity with full length Aβ monomers, and optionally said antibody shows cross-reactivity to N-terminal truncated Aβ monomers. Methods for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder employ the vaccine or antibody. Methods of detecting soluble N-terminal truncated amyloid-beta (Aβ) protofibrils/oligomers and N-terminal truncated Aβ monomers employ the antibody. | 04-26-2012 |
Par Lars Gellerfors, Lidingo SE
| Patent application number | Description | Published |
|---|---|---|
| 20100311008 | ORAL TONGUE POSITIONING DEVICE - The invention relates to a device for positioning the tongue for the treatment of disorders including snoring and obstructive sleep apnoea (OSA) and OSA Syndrome, comprising an anchoring body ( | 12-09-2010 |